Canine OA is a young dog disease (Advertorial)

Canine osteoarthritis (OA) is a debilitating condition that affects a significant number of dogs. And contrary to popular belief, OA is not just a disease of old dogs; a recent study¹ showed that almost 40% of dogs under the age of four had radiographic evidence of OA. And more importantly, the study highlighted that almost 60% of these young dogs with OA, had pain associated with their condition. These figures are staggering, especially in light of the knowledge that osteoarthritis is a consideration in quality-of-life decisions. Starting the discussion about canine OA early can significantly improve the quality of life of both dogs and their owners.

Early detection & timely pain control is crucial

A delay in diagnosing OA can result in a number of deleterious effects which eventually results in central nervous system sensitisation.² Central sensitisation can result in hyperalgesia (abnormally increased sensitivity to pain) or in more severe cases, allodynia (non-painful stimuli eliciting a painful response).³

Identifying dogs who are at increased risk of developing OA is critical so that risk factors can be controlled, and dogs can be proactively monitored for the development of clinical signs. With proper education, pet owners can play an integral role in this process. Tools to help both vets and pet owners diagnose OA as early as possible can be found by visiting the following links: LOAD questionnaire and Canine Osteoarthritis Staging Tool (COAST).

Properly managing OA in dogs requires a multimodal approach which involves adequate pain relief, body weight optimisation, physiotherapy etc. Relieving OA pain & inflammation early can help restore mobility which in turn improves muscle mass and strength and helps optimise body weight. Early intervention with a safe and effective drug is the best way to slow the vicious cycle of progressive deterioration in OA.⁴

Galliprant™ - a revolution in the treatment of canine OA pain & inflammation

Unlike traditional NSAIDs, Galliprant does NOT inhibit the cyclooxygenase enzymes and therefore it allows the production of prostaglandins involved in gastrointestinal and renal homeostasis. To learn more about Galliprant’s novel mode of action, watch this video: Galliprant™ mode of action.

Galliprant delivers the following benefits to your canine OA patients:

• Safe and effective (compared to placebo) in dogs with naturally occurring OA⁵
• Convenient once daily treatment (for long term treatment appropriate monitoring is required)
• Palatable pork flavoured tablets
• Well tolerated over 9 months at doses equivalent to 10x the max. therapeutic daily dose⁶
  • All dogs completed the study
  • No evidence of GI ulceration
  • No kidney or liver problems

Ready to step up your OA game? Click here to complete our “Early Canine OA Detection and Management” course on myElanco to win a FREE Galliprant sample valued up to $85.

Read product leaflet for full instructions.

The following mild and generally transient adverse reactions have been observed in dogs treated with grapiprant: vomiting, diarrhoea, inappetance and lethargy.

References:

1. Enomoto M et al. Prevalence of radiographic appendicular osteoarthritis and associated clinical signs in young dogs. Scientific Reports. 2024; 14(1): 2827.
2. Fox SM. Chronic Pain in Small Animal Medicine. Manson Publishing Ltd 2010: 76: Figure 69.
3. Epstein M. et al. 2015 AAHA/AAFP pain management guidelines for dogs and cats. J Am Anim Hosp Assoc. 2015; 51(2): 67-84.
4. Cachon T. et al. The Vet J. 2018; 235: 1-8.
5. Rausch-Derra L. et al. al. J Vet Intern Med. 2016; 30(3): 756-763.
6. Rausch-Derra L et al. Am J Vet Res. 2015; 76(10): 853-859.

©2024 Elanco or its affiliates. Galliprant™, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.